Financial Disclosure

Vancouver, BC – September 30, 2026 -- Lake Victoria Gold Ltd. (TSXV: LVG) has launched its first land compensation programme at Tembo, covering 111.32 acres directly over the Ngula 1 deposit in Tanzania's Lake Victoria Goldfield, with completion targeted for early October 2026.

Maiden resource at Tembo delivers 480,100 inferred ounces next to Barrick's Bulyanhulu mine

The August 11 NI 43-101 estimate for Tembo reported Inferred resources of 13.33 million tonnes at 1.12 g/t gold for 480,100 ounces, plus Indicated resources of 2.69 million tonnes at 1.16 g/t for 99,700 ounces, based on a 0.25 g/t cut-off and a US$2,400/oz gold price. At a tighter 1.00 g/t cut-off, grade rises to 2.15 g/t for 331,700 Inferred ounces and 2.00 g/t for 68,600 Indicated ounces. Ngula 1 holds roughly 56% of Inferred and 63% of Indicated ounces and is the target of a planned 4,000-to-5,000-metre close-spaced drill program.

Paris – – September 30, 2026 -- The Generation Essentials Group (NYSE: TGE; LSE: TGE) reported net profit of US$22.8 million for the six months ended June 30, 2026, a 9.9-fold increase driven by an aggressive expansion of its global hotel portfolio.

Revenue climbs 35.8% as hospitality segment surges 59.8%

Revenue from contracts with customers rose to US$30.8 million in the first half of 2026, up 35.8% year-on-year. The hotel operations, hospitality, and VIP services segment expanded 59.8%, becoming the primary growth driver following the acquisition and integration of four hotel properties in New York, Perth, Kuala Lumpur, and London.

EPS jumps 366.7% to US$0.56 as balance sheet expands to US$1.8 billion

Earnings per share increased 366.7% to US$0.56. Total assets stood at US$1.8 billion, equivalent to US$37.2 per share, while net asset value reached US$932.5 million, or US$19.2 per share.

Troy, Michigan and Chicago – September 30, 2026 -- Virtus Solis Technologies and Brae Systems have closed a 20-year Power Purchase Agreement for space-based solar power, marking the world's first commercial orbital solar PPA and a multi-billion-dollar lifetime contract commitment.

Virtus Solis will deliver 100 MW of continuous orbital solar power to Brae's subsea GPU infrastructure

Under the deal, Virtus Solis will supply 100 MW of 24/7 baseload solar power, equivalent to 876,000 MWh annually, transmitted via a dedicated receiving station to be built in Illinois. Brae holds an option to expand capacity to 250 MW, or 2.19 million MWh annually, within three years of initial commercial operations.

Riyadh – September 30, 2026 -- Dar Global, the London-listed luxury developer, posted a 66% revenue increase to US$258.0 million for the six months ended June 30, 2026, up from US$155.4 million in HY 2025.

Net profit more than doubles as margins widen across the portfolio

Gross profit climbed 85% to US$87.7 million, lifting margins to 34% from 31% a year earlier. EBITDA rose 73% to US$46.3 million, while net profit surged 149% to US$30.4 million from US$12.2 million, driven by revenue recognition on The Astera, Interiors by Aston Martin, and Neptune, Interiors by Mouawad.

Plainsboro, New Jersey – – September 30, 2026 -- Adults with overweight or obesity who switched from injectable GLP-1 therapies to the oral Wegovy pill lost an average of 4.0 kg (8.8 lb) over three months, according to new real-world data from Novo Nordisk's OCTANE study presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan on September 30, 2026.

Patients switching to the oral formulation saw rapid weight-loss gains after three months

The retrospective analysis of 194 patients on the Ro telehealth platform found that 40.7% achieved weight loss of 5% or more within three months of switching from injectable semaglutide or tirzepatide to once-daily oral semaglutide (p0.001). The proportion of participants classified with a BMI of 30 kg/m2 or higher fell by 21.6 percentage points, dropping from 87.1% at baseline to 65.5% at the three-month mark.

Groton, Conn. – September 30, 2026 -- Astrocyte Pharmaceuticals Inc. has closed a $9.5 million Series B financing round to advance Phase 2 development of AST-004, its cerebroprotective therapy for concussion, traumatic brain injury (TBI) and stroke. The round brings total capital raised by the clinical-stage biotech, including grants, to $40 million.

DeepWork Capital leads financing with four new investors joining the round

The Series B was led by DeepWork Capital, with continued backing from existing investors and new participation from MintPharma Capital, Waterstar Capital, Dynagrow Capital and Angel Star Ventures. Jackson Streeter, M.D., Venture Partner at DeepWork Capital, said the firm has been impressed by the consistency of Astrocyte's science and the progress of its clinical programs.

Singapore – – September 30, 2026 -- Kenon Holdings Ltd. has agreed to acquire a 25% equity interest in Vicinity District Energy for approximately $450 million, as part of a broader transaction valuing the company at $2.92 billion.

Antin Infrastructure Partners exits majority stake in $2.92 billion deal

The current owner, an entity related to Antin Infrastructure Partners, is selling a majority interest in Vicinity to a buyer jointly owned by Kenon and funds managed by Harrison Street Asset Management (HSAM). Under the Equity Purchase Agreement, the buyer will acquire between approximately 60% and 100% of Vicinity Holding Company. A consortium of lenders has committed non-recourse debt financing of up to $1.4 billion to fund part of the purchase price and future growth capital expenditures.

United States – – September 30, 2026 -- Smart Shooter has secured a new contract from the U.S. Joint Interagency Task Force 401 (JIATF-401) under a framework valued at up to $150 million for future delivery orders, expanding the company's footprint in the U.S. counter-drone market.

Contract Supports Domestic Shield Program Against Drone Threats

The award backs JIATF-401's Domestic Shield Program and related global missions, covering force protection, base defense, and counter-UAS requirements both domestically and overseas. Scope includes hardware, software updates, training, and support services, with the volume and timing of future orders set through individual delivery orders.

Stockholm – – September 30, 2026 -- EQT Foundation has committed more than EUR 1 million to 11 research projects across 10 institutions aimed at solving one of neuroscience's most persistent commercial barriers: getting therapeutics past the blood-brain barrier and into the central nervous system.

Eleven projects target the blood-brain barrier from different scientific angles

The funded research spans engineered biological carriers, molecular shuttles, gene therapy vectors, nanoparticles and AI-designed delivery technologies. Institutions involved are located in the Netherlands, Belgium, the United States and Canada, with initial disease applications including brain cancer, ALS and rare genetic disorders.

London – September 30, 2026 -- Clarenta Group has taken a majority stake in Leads To Development (L2D), a Paris-based preclinical and regulatory consultancy, expanding its reach into early-stage drug development ahead of first-in-human trials.

Clarenta adds non-clinical and manufacturing expertise to its clinical development platform

L2D specializes in defining development pathways, assessing preclinical evidence, troubleshooting manufacturing processes, and building regulatory strategies for biotech and pharmaceutical sponsors. The addition connects this early-stage scientific work directly to Clarenta's existing Early Phase Unit and clinical consulting capabilities.